share_log

Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $168

Benzinga ·  May 6 11:17

Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $121 to $168.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment